Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)

Exclusion criteria

• ✕. Any participant unable or not willing to sign inform consent.
• ✕. Any participant who has received systemic antibiotic within the last 14 days. Topical antibiotics are permitted. Use of metronidazole or rifaximin for treating small intestinal bacterial overgrowth (SIBO) is also permitted.
• ✕. Any participant with visible evidence of compromised skin integrity present at the catheter exist site or catheter exit site infection.
• ✕. Any participant with temporary, non-tunneled CVC or temporary PICC.
• ✕. Any participant that has received thrombolytic treatment (e.g., tissue-type plasminogen activator \[tPA\]-Cathflo), not as a part of the institution's standard of care for patency management, in current catheter within 30 days of randomization.
• ✕. Any participant with unstable arrhythmia, defined as presence of hemodynamic instability within a month prior to the baseline assessment.
• ✕. Any participant using any type of antimicrobial-coated or heparin-coated catheter.
• ✕. Any participant with documented chronic bleeding diathesis, active or recurrent bleeding within 1 month prior to randomization.